Suppression	O
of	O
the	O
pancreatic	O
duodenal	O
homeodomain	O
transcription	O
factor	O
-	O
1	O
(	O
Pdx	O
-	O
1	O
)	O
promoter	O
by	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
1c	O
(	O
SREBP	O
-	O
1c	O
)	O
.	O


Overexpression	O
of	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
1c	O
(	O
SREBP	O
-	O
1c	O
)	O
in	O
beta	O
cells	O
causes	O
impaired	O
insulin	O
secretion	O
and	O
beta	O
cell	O
dysfunction	O
associated	O
with	O
diminished	O
pancreatic	O
duodenal	O
homeodomain	O
transcription	O
factor	O
-	O
1	O
(	O
PDX	O
-	O
1	O
)	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O


To	O
identify	O
the	O
molecular	O
mechanism	O
responsible	O
for	O
this	O
effect	O
,	O
the	O
mouse	O
Pdx	O
-	O
1	O
gene	O
promoter	O
(	O
2	O
.	O
7	O
kb	O
)	O
was	O
analyzed	O
in	O
beta	O
cell	O
and	O
non	O
-	O
beta	O
cell	O
lines	O
.	O


Despite	O
no	O
apparent	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
binding	O
sites	O
,	O
the	O
Pdx	O
-	O
1	O
promoter	O
was	O
suppressed	O
by	O
SREBP	O
-	O
1c	O
in	O
beta	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O


PDX	O
-	O
1	O
activated	O
its	O
own	O
promoter	O
.	O


The	O
E	O
-	O
box	O
(	O
-	O
104	O
/	O
-	O
99	O
bp	O
)	O
in	O
the	O
proximal	O
region	O
,	O
occupied	O
by	O
ubiquitously	O
expressed	O
upstream	O
stimulatory	O
factors	O
(	O
USFs	O
)	O
,	O
was	O
crucial	O
for	O
the	O
PDX	O
-	O
1	O
-	O
positive	O
autoregulatory	O
loop	O
through	O
direct	O
PDX	O
-	O
1	O
USF	O
binding	O
.	O


This	O
positive	O
feedback	O
activation	O
was	O
a	O
prerequisite	O
for	O
SREBP	O
-	O
1c	O
suppression	O
of	O
the	O
promoter	O
in	O
non	O
-	O
beta	O
cells	O
.	O


SREBP	O
-	O
1c	O
and	O
PDX	O
-	O
1	O
directly	O
interact	O
through	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
and	O
homeobox	O
domains	O
,	O
respectively	O
.	O


This	O
robust	O
SREBP	O
-	O
1c	O
PDX	O
-	O
1	O
complex	O
interferes	O
with	O
PDX	O
-	O
1	O
USF	O
formation	O
and	O
inhibits	O
the	O
recruitment	O
of	O
PDX	O
-	O
1	O
coactivators	O
.	O


SREBP	O
-	O
1c	O
also	O
inhibits	O
PDX	O
-	O
1	O
binding	O
to	O
the	O
previously	O
described	O
PDX	O
-	O
1	O
-	O
binding	O
site	O
(	O
-	O
2721	O
/	O
-	O
2646	O
bp	O
)	O
in	O
the	O
distal	O
enhancer	O
region	O
of	O
the	O
Pdx	O
-	O
1	O
promoter	O
.	O


Endogenous	O
up	O
-	O
regulation	O
of	O
SREBP	O
-	O
1c	O
in	O
INS	O
-	O
1	O
cells	O
through	O
the	O
activation	O
of	O
liver	O
X	O
receptor	O
and	O
retinoid	O
X	O
receptor	O
by	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
and	O
22	O
-	O
hydroxycholesterol	O
inhibited	O
PDX	O
-	O
1	O
mRNA	O
and	O
protein	O
expression	O
.	O


Conversely	O
,	O
SREBP	O
-	O
1c	O
RNAi	O
restored	O
Pdx	O
-	O
1	O
mRNA	O
and	O
protein	O
levels	O
.	O


Through	O
these	O
multiple	O
mechanisms	O
,	O
SREBP	O
-	O
1c	O
,	O
when	O
induced	O
in	O
a	O
lipotoxic	O
state	O
,	O
repressed	O
PDX	O
-	O
1	O
expression	O
contributing	O
to	O
the	O
inhibition	O
of	O
insulin	O
expression	O
and	O
beta	O
cell	O
dysfunction	O
.	O
